Although initial trials of PD-1 inhibitors had mixed results [2, 3], as with previous targeted therapies, it was determined that a specific tumour genotype was required in order for these inhibitors to be effective, leading to the finding that dramatic regression of tumours could occur with the correct genotype. Here, PDCD1 is linked to neoplasm.